Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Contracts Finder |
| Notice Type: | Award notice |
| Buyer: | Sheffield Teaching Hospitals NHS Foundation Trust |
| Main Category: | Services |
| Procurement Method: | Competitive quotation (below threshold) |
| Tender Status: | Complete |
| Estimated Value (ex. VAT): | £73,258.44 |
GUSTO (STH20772) is a study for bladder cancer patients. Patients will be randomised to receive either standard care or the intervention treatment, which is selected following gene expression subtyping. Some of the patients on the intervention arm will receive the two drugs Durvalumab & Tremelimumab. Durvalumab & Tremelimumab are being provided free of charge by AstraZeneca, however, they will need to be stored and distritubed to 20 UK sites (including STH) over a 4 year period. The aim of the study is to obtain information to understand whether this approach could improve outcomes and to guide the design of a larger subsequent trial.
Published contracts in the last 12 months
144
total contracts
£671.9m
total value
£10,498,089
average contract size
Typical categories
Provision of IVF Media consumables
Sheffield Teaching Hospitals NHS Foundation Trust · WAC-530569
System One Re-procurement
Sheffield Teaching Hospitals NHS Foundation Trust · WAC-444872
Microsoft Licences - N365
Sheffield Teaching Hospitals NHS Foundation Trust · WAC-444887
Pipeline status
Not addedContract imported automatically · AI writes the response
Application Deadline
10 July 2023
Closed
Estimated Value
£73,258.44
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Release Date: |
| 10 July 2023 |
| Application Deadline: | 10 July 2023 |
| Procurement ID (OCID): | ocds-b5fd17-b3472db5-cf52-4236-aecf-26360c6d8c06 |
| Notice Reference: | b3515af5-d325-47e5-8ec2-269837d99de3-661250 |
View Original Notice
Access the full notice on the official portal